Naples Global Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 18.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 30,083 shares of the biopharmaceutical company’s stock after acquiring an additional 4,665 shares during the period. Naples Global Advisors LLC’s holdings in Pfizer were worth $1,090,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer in the 2nd quarter valued at $103,000. Herndon Capital Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at $120,000. Americafirst Capital Management LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at $127,000. Private Vista LLC grew its holdings in shares of Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 190,933 shares during the period. Finally, Lipe & Dalton grew its holdings in shares of Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 300 shares during the period. 71.16% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer Inc. (NYSE PFE) opened at $36.33 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43. The company has a market cap of $218,946.36, a PE ratio of 13.88, a price-to-earnings-growth ratio of 2.07 and a beta of 0.91.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same period in the previous year, the firm posted $0.47 EPS. The company’s revenue for the quarter was up .6% on a year-over-year basis. sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer announced that its Board of Directors has initiated a share buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.
A number of equities analysts recently weighed in on PFE shares. UBS set a $40.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Sanford C. Bernstein set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research note on Wednesday, January 17th. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price for the company in a research note on Thursday, November 23rd. Finally, Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $39.40.
In other Pfizer news, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Mikael Dolsten sold 13,986 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $35.85, for a total transaction of $501,398.10. Following the sale, the insider now directly owns 120,884 shares in the company, valued at $4,333,691.40. The disclosure for this sale can be found here. Insiders have sold a total of 248,037 shares of company stock worth $9,064,785 over the last three months. Insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Naples Global Advisors LLC Has $1.09 Million Holdings in Pfizer Inc. (PFE)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/03/20/naples-global-advisors-llc-has-1-09-million-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.